Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jun Ito

Showing results (231-240 of 241) with videos related to

Pageof 25
Sort By:
Kidney International Reports|April 30, 2025
Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving TolvaptanKiyotaka Uchiyama, Daisuke Kamano, Tomoki Nagasaka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 21, 2020
Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteriaTakuya Sho, Goki Suda, Koji Ogawa, et al.
Scientific Reports|November 29, 2025
Simplified monitoring of sofosbuvir/velpatasvir in Japanese patients with chronic hepatitis C based on a retrospective analysis of a prospective multicenter cohortGoki Suda, Masaru Baba, Yoshiya Yamamoto, et al.
The Plant Journal : for Cell and Molecular Biology|March 28, 2023
MORE PANICLES 3, a natural allele of OsTB1/FC1, impacts rice yield in paddy fields at elevated CO<sub>2</sub> levelsToshiyuki Takai, Yojiro Taniguchi, Megumu Takahashi, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 10, 2021
Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteriaTakuya Sho, Goki Suda, Koji Ogawa, et al.
Abdominal Imaging|January 13, 2015
Intratumoral artery on contrast-enhanced computed tomography imaging: differentiating intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinomaSeiji Tsunematsu, Makoto Chuma, Toshiya Kamiyama, et al.
Cancers|August 26, 2022
Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150Takuya Sho, Goki Suda, Yoshiya Yamamoto, et al.
The Journal of Infection|February 28, 2026
Tenofovir alafenamide prevents HBV reactivation in anticancer/immunosuppression: 24-month multicentre prospective studyGoki Suda, Masatsugu Ohara, Masaru Baba, et al.
Liver Cancer|June 16, 2023
Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab TreatmentShunichi Hosoda, Goki Suda, Takuya Sho, et al.
Journal of Medical Virology|January 4, 2023
Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitisGoki Suda, Masaru Baba, Yoshiya Yamamoto, et al.
Pageof 25

Showing results (231-240 of 241) with videos related to

Sort By:
Pageof 25
Kidney International Reports|April 30, 2025
Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving TolvaptanKiyotaka Uchiyama, Daisuke Kamano, Tomoki Nagasaka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 21, 2020
Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteriaTakuya Sho, Goki Suda, Koji Ogawa, et al.
Scientific Reports|November 29, 2025
Simplified monitoring of sofosbuvir/velpatasvir in Japanese patients with chronic hepatitis C based on a retrospective analysis of a prospective multicenter cohortGoki Suda, Masaru Baba, Yoshiya Yamamoto, et al.
The Plant Journal : for Cell and Molecular Biology|March 28, 2023
MORE PANICLES 3, a natural allele of OsTB1/FC1, impacts rice yield in paddy fields at elevated CO<sub>2</sub> levelsToshiyuki Takai, Yojiro Taniguchi, Megumu Takahashi, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 10, 2021
Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteriaTakuya Sho, Goki Suda, Koji Ogawa, et al.
Abdominal Imaging|January 13, 2015
Intratumoral artery on contrast-enhanced computed tomography imaging: differentiating intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinomaSeiji Tsunematsu, Makoto Chuma, Toshiya Kamiyama, et al.
Cancers|August 26, 2022
Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150Takuya Sho, Goki Suda, Yoshiya Yamamoto, et al.
The Journal of Infection|February 28, 2026
Tenofovir alafenamide prevents HBV reactivation in anticancer/immunosuppression: 24-month multicentre prospective studyGoki Suda, Masatsugu Ohara, Masaru Baba, et al.
Liver Cancer|June 16, 2023
Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab TreatmentShunichi Hosoda, Goki Suda, Takuya Sho, et al.
Journal of Medical Virology|January 4, 2023
Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitisGoki Suda, Masaru Baba, Yoshiya Yamamoto, et al.
Pageof 25